drugset
drugset / Trial / NCT06964165

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

NCT06964165 ↗

Phase 2 Terminated 36 enrolled Tesaro, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of the study is to learn whether Niraparib or Platinum-Taxane Doublet chemotherapy is better in treating participants with Homologous Recombination Deficient (HRd) Stage III/IV Ovarian Cancer (OC). This study is a sub-study of the Master protocol -OPAL (NCT03574779)

Timeline

Start
2022-04-14
Primary completion
2024-06-28
Completion
2025-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule — —
Subject Niraparib Small molecule — —
Subject Paclitaxel Small molecule — —

Indications

ovarian neoplasm